Physician profile
Jeffrey Stephens
NPI 1417900846
$194,887.07
in general payments reported to CMS, 2019-2025
29 companies · $17K in 2025
The $17K reported for 2025 was more than what 96% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $14K · 2021: $29K · 2022: $35K · 2023: $48K · 2024: $19K · 2025: $17K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $64K · Honoraria: $10K · Food and Beverage: $7,521 · Travel and Lodging: $1,942 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $64,315.00 |
| Honoraria | $10,150.00 |
| Food and Beverage | $7,520.72 |
| Travel and Lodging | $1,942.14 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $87,063.99 | 2021-2025 | Vraylar |
| Supernus Pharmaceuticals, INC. | $54,915.70 | 2021-2025 | Qelbree, Qelbree |
| Allergan, INC. | $46,554.31 | 2019-2020 | |
| Ironshore Pharmaceuticals INC. | $1,182.80 | 2020-2024 | Jornay Pm |
| Takeda Pharmaceuticals U.S.A., INC. | $903.35 | 2019-2025 | Trintellix |
| Tris Pharma INC | $582.15 | 2020-2025 | Dyanavel Xr |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $528.44 | 2021-2025 | Caplyta |
| Vanda Pharmaceuticals INC. | $393.05 | 2020-2025 | Hetlioz, Fanapt |
| Otsuka America Pharmaceutical, INC. | $362.39 | 2019-2025 | Rexulti, Nuedexta |
| Corium, LLC | $352.59 | 2022-2025 | Azstarys |
| Bausch Health US, LLC | $289.58 | 2019-2024 | Aplenzin |
| Neos Therapeutics, LP | $253.38 | 2020-2025 | Adzenys Xr-Odt, Cotempla Xr-Odt, Exxua |
| Sunovion Pharmaceuticals INC. | $242.14 | 2019-2022 | |
| Lundbeck LLC | $235.58 | 2019-2024 | Rexulti |
| Collegium Pharmaceutical, INC. | $186.41 | 2025 | Jornay Pm |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $144.98 | 2021-2025 | Loreev Xr, Sertraline Hcl |
| Noven Therapeutics, LLC | $143.30 | 2024-2025 | Xelstrym, Secuado |
| Idorsia Pharmaceuticals US INC | $127.67 | 2023-2025 | Quviviq, Quviviq |
| Axsome Therapeutics, INC. | $124.29 | 2023-2025 | Auvelity |
| Alkermes, INC. | $67.08 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $50.77 | 2023 | Austedo Xr, Austedo |
| Janssen Pharmaceuticals, INC | $45.63 | 2019-2021 | |
| Neurocrine Biosciences, INC. | $31.45 | 2025 | |
| Arbor Pharmaceuticals, INC. | $27.65 | 2019 | |
| Rhodes Pharmaceuticals L.P. | $20.83 | 2019 | |
| Vertical Pharmaceuticals, LLC | $19.04 | 2025 | Relexxii |
| Alfasigma USA, INC. | $13.73 | 2022 | |
| Eisai INC. | $12.69 | 2022 | |
| Shire North American Group INC | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Stephens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.